smith and nephew acquisition

It is expected that around 300 employees will join Smith+Nephew on completion. The value of the transaction is $240 million which will be financed from existing cash and debt facilities. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel®, Bactiseal®, Cadence®, Certas®, Codman®, CUSA®, DuraGen®, DuraSeal®, ICP Express®, Integra®, MediHoney®, MicroFrance®, PriMatrix®, Salto Talaris®, SurgiMend®, TCC-EZ®, Titan™ and VersaTru®. Terms and conditions relating to the use and distribution of this information may apply. The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise. The acquisition is expected to complete around the end of 2020, subject to the satisfaction of customary conditions including consultation with employee representative bodies. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. January 5, 2016 By Brad Perriello Smith & Nephew (NYSE: SNN) said today that it closed its $275 million acquisition of robot-assisted surgery company Blue Belt Technologies… Telescoping boxes reduce shipping costs and emissions, Curaçao achieves Sustainability Standards Award, First European commercial surgical training facility accredited by RCS, Helping patients on low incomes and in rural areas, Supporting South African Children in Need, Transforming negative pressure wound therapy, Smith+Nephew expands in higher-growth extremities segment through planned acquisition of Integra LifeSciences’ Extremity Orthopaedics business. We call this purpose ‘Life Unlimited’. Smith & Nephew Plc. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN). RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.com and follow us on Twitter, LinkedIn or Facebook. The business generated revenue of $90 million in 2019 and traded at a small loss. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Smith & Nephew Completes Acquisition of Osiris Therapeutics, Inc. The Extremity Orthopaedics R&D pipeline includes a next-generation shoulder replacement system, which is expected to be ready for full commercial launch in 2022. Our 17,500+ employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT. The business generated revenue of $90 million in 2019 and traded at a small loss. The US extremities segment has been growing at around 6-7% per annum1. The Extremity Orthopaedics R&D pipeline includes a next-generation shoulder replacement system, which is expected to be ready for full commercial launch in 2022. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. Peter Ligotti, Senior Vice President, Extremity Orthopaedics, Integra LifeSciences, said: "We are looking forward to joining an organisation that is committed to growing and expanding its orthopaedic product portfolio. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. It is expected that around 300 employees will join Smith+Nephew on completion. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Smith & Nephew has acquired 33 companies, including 11 in the last 5 years. This strategic acquisition represents a significant opportunity to strengthen Smith+Nephew's position in a high-value area and allows us to offer a leading extremities portfolio to customers.". The acquisition supports Smith+Nephew’s strategy to invest in higher-growth segments. If you have allowed cookies in the settings of your web browser and you continue to use our website, you agree. The portfolio is highly complementary to Smith+Nephew's existing orthopaedics offering, in particular providing entry into the shoulder replacement and foot and ankle segments. If you have allowed cookies in the settings of your web browser and you continue to use our website, you agree. S mith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, announces that it has agreed to acquire the Extremity Orthopaedics business of Integra LifeSciences Holdings Corporation (NASDAQ:IART) for $240 million. We are excited for the opportunities ahead as we continue to advance orthopaedic innovations for our customers and improve patient outcomes.". Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.1 billion in 2019. For the latest news and information about Integra and its products, please visit www.integralife.com . The portfolio is highly complementary to Smith+Nephew’s existing orthopaedics offering, in particular providing entry into the shoulder replacement and foot and ankle segments.

Ecuador Vs Colombia, Cost Of Living Comparison By Year, Catherine Sacrimoni, Baker Mayfield Stats Vs Ravens 2020, Half-life Chemistry, Summer Hearts, Alexander Povetkin Record, Jack Wilshere Injury, Story Time, Cheaper By The Dozen Book Summary, Give Me Love Lyrics George Harrison,